Long-Acting PYY RA
Obesity, Cardio-Renal-Metabolic Diseases
Pre-clinicalActive
Key Facts
Indication
Obesity, Cardio-Renal-Metabolic Diseases
Phase
Pre-clinical
Status
Active
Company
About i2o Therapeutics
i2o Therapeutics is a private, pre-clinical stage biotech focused on unlocking the potential of oral biologic drugs through its proprietary intestinal targeting delivery platform. The company's strategy centers on developing long-acting oral versions of key metabolic hormones, including GLP-1, amylin, PYY, and glucagon receptor agonists, with an eye toward combination therapies for obesity and related conditions. As a platform company, it is pre-revenue and likely backed by venture capital, positioning itself in one of the most competitive and high-value therapeutic areas in biopharma.
View full company profileTherapeutic Areas
Other Obesity, Cardio-Renal-Metabolic Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Long-Acting GLP-1 RA (Asset 1) | i2o Therapeutics | Pre-clinical |
| Long-Acting GLP-1 RA (Asset 2) | i2o Therapeutics | Pre-clinical |
| Long-Acting Amylin DACRA (Asset 1) | i2o Therapeutics | Pre-clinical |
| Long-Acting Amylin DACRA (Asset 2) | i2o Therapeutics | Pre-clinical |
| Long-Acting Glucagon RA | i2o Therapeutics | Pre-clinical |